Health AI Central
Peer-Reviewed Publication
medRxiv2025September 7, 2025Journal Article

Candidate Correlates of Protection in the HVTN505 HIV-1 Vaccine Efficacy Trial Identified by Positive-Unlabeled Learning.

Shiwei Xu1, Aaron Hudson2, Holly E Janes2, Georgia D Tomaras3, Margaret E Ackerman1,4,5
1Quantitative Biomedical Sciences Program, Dartmouth College, Hanover, NH USA.
2Biostatistics, Bioinformatics and Epidemiology Program, Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, WA, USA.
3Department of Surgery, Center for Human Systems Immunology, Duke University, Durham, SC, USA.
4Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
5Thayer School of Engineering, Dartmouth College, Hanover, NH, USA.
PubMed PMC DOI PDF

Abstract

With a goal of unveiling mechanisms by which vaccines can provide protection against HIV-1 acquisition, several studies have explored correlates of risk of HIV-1 acquisition in HVTN 505, which was a phase IIb trial conducted to assess the safety and efficacy of a DNA plasmid and recombinant adenovirus serotype 5-vectored HIV vaccine regimen among individuals in the United States who were vulnerabl…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.